Pfizer loses at CAFC on length of a patent term adjustment (“PTA”) for U.S. Patent No. 8,153,768
Judge Newman dissented:
I respectfully dissent.
The panel majority’s ruling on patent term
adjustment is in conflict with the
Patent Act, for the PTO’s
admittedly incomplete restriction require-
ment during patent examination
contributed to the delay
in issuance of the patent.